Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hi KonarA
No we don't but LD was excited by the prospect when we were awaiting one outcome just after the last update. So I expect that we could have 1 or 2 extra 1st Scans to add to the data.
Chester.
The future for Scancell hinges on progress in the trials and the success of the science 'possibility' becoming science 'fact'.
There are four thresholds that we await to cross, by successfully passing each one the 'what if's' change to 'how encompassing and valuable' will Scancell's Platform's' be.
SCIB1 + CPI : Can the ORR % move into the mid 90's with the remaining patients reaching 1st Scans.
MODI1 + CPI : Is the same uplift in ORR seen in the two remaining Cancer Cohorts, Renal and Head & Neck. If we see that the checkpoints protect the Moditope created 'T' Cells ( as is the case with SCIB1 ) and the battles inside those tumours start to show Stability, Regression and Removal we could move towards another Registration Trial.
MODI1 + CPI Resected Tumours : Will we see the compelling 'T' Cell activity sort after by Large Pharma in those removed tumours. The first of which may be analyse in our lab in the next 3/4 weeks.
iSCIB+ : A few months away yet, but confirmation that it is also non-toxic, it increases the ORR as in SCIB1 and how well does AvidiMab do in increasing the ORR still further or even if it increases the patient pool further.
These four steps forward all added together will mean Scancells potential will not be doubted and should lead to large investors taking positions because the potential of a buy out will become very probable.
Tuesday could begin to throw some light on the direction of travel.
Chester.
TF
If Tuesdays presentation is purely as you say 'to engage with investors or analysts' with nothing new to add to the story so far, I will be very disappointed in their use of management time.
We know that even with 61 staff that they are extremely busy running the trials, engaging with clinicians and developing the science.
What would the rationale behind organising a presentation with nothing new to make it worthwhile ?
You cannot be serious in thinking that my observation is not a valid point to post about.
Chester.
I think there are many of us that feel the tide is forever going out, but, the data coming from Scib1 + checkpoints has so far been outstanding. I cannot see any logical reason to be giving a presentation on Tuesday that is just going over old ground.
As Violindog pointed out, if its not new data who are they trying to engage. The money is in the bank and we know more or less where we are up to on both trials, iSCIB+ has been approved. What else can it be that warrants a presentation.
It has to be an extra bit of something.
Chester.
Ahh !
Very Good point Violindog
I think that line relates to a past presentation only so Bobbust is potentially correct that next Tuesday's presentation could cover both trials.
One thing that I expect is the SCIB1 + CPI will be reporting on a higher number of patients who have had their first scans pushing the Overall Response Rate ( ORR ) over 90% and maybe a little higher.
Chester.
By clicking on the link in the RNS :
https://www.lsegissuerservices.com/spark/ScancellHoldings/events/f581274b-146c-4a89-af15-05bcae874775
It does say 'Positive data from Phase 2 SCOPE trial with SCIB1'
Chester.
Hi Chelsea7
Its good to have you posting on here again.
I think we are mighty close to our Scancell investments being past the gambling stage.
Two major pieces of news will, to my mind, take the 'what if' worry out of the equation.
1 ) Will the Checkpoint Inhibitors do the same job for MODI1 as they have done for SCIB1 ?
2 ) Does iSCIB+ produce the same of better results as SCIB1 with the Checkpoints and is the 'non-toxicity' the same ?
If we achieve both of the above then the days of 'hoping' Scancell is a good investment are over and we will enter a stage where the question will be, "do we go it alone and become the UK's version of BionTech or what price for a complete by out.
I do hope these things come about and you can get back in early enough to reap the rewards you deserve for all your years of patiently waiting.
Chester.
Hi BOJO
I'm no expert on how BioTech's interact at the enquiry level but we do know that NDA's form a basis for opening discussions. I see no reason why an NDA could not extend to proving the capability of increasing the Avidity of an existing Mab product.
Maybe we are already doing that in-house as part of our sales and marketing budget.
Chester.
Hi VanVan
I've been out all day so only just had chance to respond. I think miavoce's reply is a good part of where we are on the deals front.
My honest take on AvidiMab is that it has the potential to be taken up by dozens of Mab related Biotech and Pharma Companies but it will take time to convince them and then lab test each new product. When the first deal is signed it will give confidence to other Co's to test AvidMab on their products. This process could take another year at least. When AvidiMab has been proven to improve the Avidity of a third party Mab and that translates to better clinical outcomes in an already licensed product, it will lead to even more deals.
The GlyMab situation is different because GenMab have already given the first green light and stumped up £5M to tie up an exclusive deal for a Target ( Oct 22 ). It was way easier to sell that to GenMab because they have known and worked with Scancell for many years. We still need to hear that GenMab are going to enter a Ph1 Trial using our GlyMab Target.
Selling other GlyMabs or 'Target of a GlyMab' will take a lot of time but getting another deal over the line will make the next deal easier and so on.
I'm not convinced we will see much in the way of new deals in 2024 but its pretty obvious that Scancell are already having multiple discussions on both AvidiMab and the GlyMabs, hopefully any potential buyers will be in a rush to get a deal done.
So much can happen this year and let's hope it's at least a continuation of strong and positive results across all cohorts of both trials.
Chester.
Hi VanVan
I agree with you that Scancell has had to react as the science / investment picture changed. Their was a fantastic article linked on here in the last few weeks that talked about the strategy being employed by many BioTechs.
Under the guidance of our new ( 12 months + ) Chairman we have ensured that cash is in place to allow some freedom of choice over the next year and a half.
Our CEO has said a few times that as the trials progress and the data becomes more compelling the deeper any suitor will have to go into their pockets.
It does seem that the SCOPE Trial is on track to produce results that the owner of the Checkpoint Inhibitors will find it almost impossible to resist. If SCIB1 and then iSCIB+ pan out as hoped for in the recent RNS, Bristol Myers Squibb could see an opportunity to be dominant in that market. The addition of AvidiMab would give an extended patent life of 15 years.
If the ModiFY Trial shows similar results in the Checkpoint Inhibitor cohorts both of our platforms will become very coveted by many Large Pharma Cos, as many of them need to build their future pipelines with cutting edge treatments.
As has been the mantra here for many years, what creates the value is 'data data data' and 2024 should see enough clinical results to finally get the share price on its way beyond 30p. Add to that the values of any deals done for either GlyMabs or AvidiMab.
Could be a fantastic year for you if Scancell take off and Greatland Gold start bringing Havieron to life.
Chester.
Great summation to my Question, thanks Ray,
It will be a glorious day when the long dreamed of potential actually translates into to patients being given their lives back. It is one thing to be an investor in Scancells endeavours and not knowing if that day will actually come about.
To be someone told that there is nothing further that can be done in their struggle against their illness and then in the 'last chance saloon' Immunobody gives them back years of life to enjoy with loved ones ....... that is amazing. Where we could be in 5 years time probably looks like science fiction in 2024.
Fingers crossed it comes about and progresses as you have outlined.
Chester.
After re-reading the SCOPE Trial update dated 27th November 23, I have a question ?
Taken from that RNS :
"The SCOPE trial has now successfully transitioned into the second stage, which will recruit a further 27 patients (for a total of 43). The aim is to achieve at least 18 further responses (i.e., 27 responses in total) which would statistically demonstrate that SCIB1, in combination with doublet therapy, exceeds currently achievable ORRs. Recruitment is on track with data available in H1 2024. Based upon the first 13 patients there is a greater than 90% probability that the second phase will also be successful.
If validated in the second stage of the SCOPE trial this will provide confidence to initiate a randomised phase 2/3 adapted registration programme in patients with unresectable melanoma which represents a potential $1.5 billion per annum market. The Phase 2 part of the adapted trial should take 18 months and will likely generate significant partner interest".
So if the success of SCIB1 Monotherapy can open up a $1.5B yearly market, does that mean that if iSCIB+ is just as successful that the yearly market size becomes somewhere around $3.75B ?
Chester.
Hi Defender90
The market simply wants to see value.
A milestone payment from GenMab or another Deal with GenMab, with an another upfront payment.
A new Pharma co or two doing deals for one or more of our GlyMabs or an AvidiMab deal.
Trial Wise :
The number of positive responses on the Scope Trial going past 30 patients and reaching 90% ORR.
Outstanding results from the early patients on Modi1 + Checkpoints, showing tumour reduction.
All of the above would not only raise the SP but start to persuade Institutional Investors to take longterm position.
I think a tipping point could be created by a combination of 'Positive Trial Data' and 'Deals' involving cash that will start the journey towards Violindog's 50p target.
Chester.
I agree C11
'Those that follow the science' is probably a better way of putting it.
I really do hope we see some data for the first few patients on Modi1 + Checkpoints. It is a piece of the puzzle I'm waiting for with the hope it's on par with the Scope achievements.
Chester.
The important issue is that the current SP is stuck very close to the fund raise. This can only break upwards on positive news. Either trial related or deals.
The worth of the SCOPE, iSCIB+ approval is yet to be seen but as LTH's we can see how it could impact on the future value of the company.
In the next week or so, we could have new information on both Trials as some patients will have reached and passed their 1st Scans for SCIB1+ CPI and MODI1 + CPI since the last updates.
The 6 month assessment by a 'Large Pharma Co' on our GlyMabs should be complete and a decision or discussions being held.
A remote possibility that GenMab have decided to register for a Phase1 trial, triggering a small Milestone. They were even interested in another target / Mab, so news on that could be imminent.
All of the above are the kind of positive announcements that will get the SP moving back towards 20p. Which I feel we should already be at.
Chester.
Scancell's share price is currently floating around 11p even though we have two incredible trials running, 61 highly capable staff and roughly £15m in cash.
Back when we had 230m shares in issue and only the promise of what Immunobody or Moditope could achieve the share price was circa 5p.
I remember thinking what a steal 5p was set against the potential waiting to be unlocked.
I'm back to thinking the same now about 11p.
Based only on the data released so far from the SCOPE trial and the confidence shown by LD in the potential of iSCIB+. Added to that, If Modi1 + CPI'S has anything like the same impact on positive treatment outcomes 11p becomes a serious joke.
When we reach the end of this year I honestly think we will look back at this current 11p as a gift for those that took advantage.
To all Scancell shareholders I say, 'stay patience and keep the faith' 2024 is already loaded up with the potential of many inflection points.
Chester.
Hi C7
Great to hear from you.
This excellent and timely RNS does set up the Iterim Report very nicely.
I'm not interested in how the market reacts at this time as the importance of each of these excellent pieces of news is that they continue to add value going forward.
Chester.
Hi TF
The fact is that three new investors have taken a position in the last cash raise. We can only presume that they did some Due Diligence and they were not just having a punt.
We have been told that Large Pharma wants to see solid data, the kind that reduces the risk of a bad investment.
Our new found investors will have the appetite for a little more risk / reward. So I'm delighted to see them on board.
The next set of 'Positive' data results will see Scancell taken very seriously.
Chester.